Last reviewed · How we verify

Flucelvax seasonal vaccine

University of Minnesota · Phase 1 active Biologic Quality 15/100

Flucelvax seasonal vaccine is a Biologic drug developed by University of Minnesota. It is currently in Phase 1 development.

At a glance

Generic nameFlucelvax seasonal vaccine
SponsorUniversity of Minnesota
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Flucelvax seasonal vaccine

What is Flucelvax seasonal vaccine?

Flucelvax seasonal vaccine is a Biologic drug developed by University of Minnesota.

Who makes Flucelvax seasonal vaccine?

Flucelvax seasonal vaccine is developed by University of Minnesota (see full University of Minnesota pipeline at /company/university-of-minnesota).

What development phase is Flucelvax seasonal vaccine in?

Flucelvax seasonal vaccine is in Phase 1.

What are the side effects of Flucelvax seasonal vaccine?

Common side effects of Flucelvax seasonal vaccine include Pain, Irritability, Decreased appetite, Nasopharyngitis, COVID-19, Somnolence.

Related